结缔组织病相关肺动脉高压的研究进展分析
摘要
结缔组织病患者死亡的重要原因之一。近年来，结缔组织病相关的肺动脉高压引起了世界的广泛关注。由于其临床表现隐匿，
不易发现，且发病机制尚不明确，故常会被忽略。本文关于结缔组织病伴肺动脉的发病机制、临床特点、治疗做一论述。
关键词
全文:
PDF参考
[1] 王慧 , 潘晴 , 王宙明 , 等 . 混合性结缔组织病相关肺
动脉高压临床特点分析 [J]. 天津医药 , 2024,52(07):701-704.
[2] Liu S F, Nambiar V N, Li Q, et al. Pulmonary
hypertension: Linking inflammation and pulmonary arterial
stiffening[J]. Front Immunol, 2022(13):959209.
[3] Yaku A, Inagaki T, Asano R, et al. Regnase-1 Prevents
Pulmonary Arterial Hypertension Through mRNA Degradation
of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar
Macrophages[J]. Circulation, 2022,146(13):1006-1022.
[4] Hu Y, Chi L, Kuebler W M, et al. Perivascular
Inflammation in Pulmonary Arterial Hypertension[J]. Cells,
2020,9(11).
[5] Koga T, Ichinose K, Kawakami A, et al. The role of
IL-17 in systemic lupus erythematosus and its potential as a
therapeutic target[J]. Expert Rev Clin Immunol, 2019,15(6):629-
637.
[6] Shi T Y, Wen X H, Meng J, et al. Effect of IL-17 on
pulmonary artery smooth muscle cells and connective tissue
disease-associated pulmonary arterial hypertension[J]. Immun
Inflamm Dis, 2024,12(4):e1243.
[7] Krzyzewska A, Kurakula K. Sex Dimorphism in
Pulmonary Arterial Hypertension Associated With Autoimmune
Diseases[J]. Arterioscler Thromb Vasc Biol, 2024,44(10):2169-
2190.
[8] Dhaun N, Webb D J. Endothelins in cardiovascular
biology and therapeutics[J]. Nat Rev Cardiol, 2019,16(8):491-502.
[9] Kawashiri S Y, Ueki Y, Terada K, et al. Improvement
of plasma endothelin-1 and nitric oxide in patients with systemic
sclerosis by bosentan therapy[J]. Rheumatol Int, 2014,34(2):221-
225.
[10] Masi S, Georgiopoulos G, Alexopoulos G, et al. The
complex relationship between serum uric acid, endothelial
function and small vessel remodeling in humans[J]. Journal of
Clinical Medicine, 2020, 9(7): 2027.
[11] Meng L, Teng X, Liu Y, et al. Vital Roles of Gremlin-1
in Pulmonary Arterial Hypertension Induced by Systemic-to-
Pulmonary Shunts[J]. J Am Heart Assoc, 2020,9(15):e16586.
[12] Zhao Q, Zhang R, Shi J, et al. Imaging Features in
BMPR2 Mutation-associated Pulmonary Arterial Hypertension[J].
Radiology, 2023,307(5):e222488.
[13] Wang L, Moonen J R, Cao A, et al. Dysregulated
Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary
Hypertension[J]. Circ Res, 2023,132(5):545-564.
[14] Huang C, Yang J, Li M T, et al. CBLN2 rs2217560 was
Associated with Pulmonary Arterial Hypertension in Systemic
Lupus Erythematosus[J].Chin Med J (Engl), 2018,131(24):3020-
3021.
[15] Pousada G, Lago-Docampo M, Baloira A, et al.
Pulmonary arterial hypertension associated to systemic
erythematosus lupus: molecular characterization of 3 cases[J]. Med
Clin (Barc), 2018,151(3):111-115.
[16] Hjalmarsson C, Kjellstrom B, Jansson K, et al. Early
risk prediction in idiopathic versus connective tissue disease-
associated pulmonary arterial hypertension: call for a refined
assessment[J]. ERJ Open Res, 2021,7(3).
[17] 杨金良 , 任占芬 , 罗寰 , 等 . 结缔组织病相关肺动脉
高压的临床特点及预后危险因素分析 [J]. 重庆医科大学学报 ,
2022,47(06):745-752.
[18] Zhao J, Wang Q, Liu Y, et al. Clinical characteristics
and survival of pulmonary arterial hypertension associated with
three major connective tissue diseases: A cohort study in China[J].
Int J Cardiol, 2017,236:432-437.
[19] Distler O, Ofner C, Huscher D, et al. Treatment
strategies and survival of patients with connective tissue disease
and pulmonary arterial hypertension: a COMPERA analysis[J].
Rheumatology (Oxford), 2024,63(4):1139-1146.
(5 摘要 Views, 14 PDF Downloads)
Refbacks
- 当前没有refback。